Shipping services continue despite COVID-19 outbreak ! Click here to view COVID-19 related products

YM155 (Sepantronium Bromide)

For research use only.

Catalog No.S1130

133 publications

YM155 (Sepantronium Bromide) Chemical Structure

CAS No. 781661-94-7

YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 110 In stock
EUR 68 In stock
EUR 117 In stock
EUR 265 In stock
EUR 439 In stock
EUR 756 In stock
EUR 1248 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's YM155 (Sepantronium Bromide) has been cited by 133 publications

Purity & Quality Control

Choose Selective Survivin Inhibitors

Biological Activity

Description YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Phase 2.
Targets
Survivin [1]
(HeLa-SURP-luc, CHO-SV40-luc cells)
0.54 nM
In vitro

YM155 is not sensitive to survivn gene promoter-driven luciferase reporter activity even at 30 μM. YM155 significantly inhibits endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC-3 and PPC-1 with a concomitant increase in caspase-3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50 from 2.3 to 11 nM, respectively. [1] YM155 increases the sensitivity of NSCLC cells to γ-radiation. The combination of YM155 and γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. YM155 delays the repair of radiation-induced double-strand breaks in nuclear DNA. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kasumi-1 NV7LOIJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LycVczKGh? NFzoV3pFVVOR MWjJR|UxRTBwMEC5JOKyKDBwMECwPUDPxE1? MoTONlU3PTl5M{G=
M-07e NFHWWoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHudZU4OiCq M3nIVGROW09? M1PnTWlEPTB;MD6wOFAhyrFiMD6wNVMh|ryP M{PV[|I2PjV7N{Ox
THP-1 M3zHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrsO|IhcA>? MlTBSG1UVw>? NEflXVFKSzVyPUCuNFUyKMLzIECuNFE{KM7:TR?= NWPGbpBYOjV4NUm3N|E>
CMK NHrYN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPLTZhTPzJiaB?= MXzEUXNQ Mo\ETWM2OD1yLkC1N{DDuSByLkCwPUDPxE1? NVPRPVh7OjV4NUm3N|E>
MV4-11 M1XzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TUVVczKGh? Mn3MSG1UVw>? MnnpTWM2OD1yLkC1OUDDuSByLkCyPEDPxE1? MmnxNlU3PTl5M{G=
AML-193 MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXe3NkBp MlmySG1UVw>? NF[1TolKSzVyPUCuOFYzKMLzIECuNFYxKM7:TR?= NInjWXgzPTZ3OUezNS=>
HL-60 MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;Ne|czKGh? MULEUXNQ NEjFcFdKSzVyPUCuNFAyKMLzIECuNFAxOiEQvF2= NEOzZlYzPTZ3OUezNS=>
ML-2 NVjDfWJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LaZlczKGh? MX\EUXNQ M2DMb2lEPTB;MD6wNFkhyrFiMD6wNFIh|ryP MWGyOVY2QTd|MR?=
OCI/AML3 NX36N4ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvsO|IhcA>? Mk\SSG1UVw>? M1HFSWlEPTB;MD6wNVEhyrFiMD6wNFIh|ryP MWqyOVY2QTd|MR?=
HEL Ml[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2f0W|czKGh? M4PidGROW09? MWDJR|UxRTBwNUW5JOKyKDBwMEO4JO69VQ>? M17wclI2PjV7N{Ox
ME-1 MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;qfWJOPzJiaB?= M3;vW2ROW09? M1K0SWlEPTB;MD62PFQhyrFiMD6xO|kh|ryP M2j2RVI2PjV7N{Ox
THP-1 MoTFRZBweHSxc3nzJGF{e2G7 MUOxxsDPxE1? Mof3O|IhcA>? MkXWSG1UVw>? M{i5WYlv\HWlZYOgZZBweHSxc3nz MmnQNlU3PTl5M{G=
M-07e NG\4eYhHfW6ldHnvckBCe3OjeR?= MUew5qCUOcLizszN NHK5[Xg4OiCq M1KzVGROW09? MXzpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw NXLSN3o2OjV4NUm3N|E>
THP-1 NVW0bYU6TnWwY4Tpc44hSXO|YYm= NYq0dG5vOOLCk{JCpO69VQ>? NXPadG9PPzJiaB?= M{DhPGROW09? MYDpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw MlXSNlU3PTl5M{G=
CMK MXXGeY5kfGmxbjDBd5NigQ>? NVfGcXlwOOLCk{JCpO69VQ>? NIrx[Io4OiCq NIDvVlJFVVOR M{nEeIlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= NGXTUXYzPTZ3OUezNS=>
AML-193 NE\YSVhHfW6ldHnvckBCe3OjeR?= NHTtTGQx6oDVMdMg{txO NHOwR5o4OiCq NGnCc5JFVVOR NIe5W3ZqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu NHn5RW4zPTZ3OUezNS=>
Kasumi-1 M{fnT2Z2dmO2aX;uJGF{e2G7 NEPXcHcx6oDVMdMg{txO NHzRZoo4OiCq M2X6UWROW09? NH;kNG9qdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu Mm\QNlU3PTl5M{G=
MV4-11 NEKxVG5HfW6ldHnvckBCe3OjeR?= MYCw5qCUOcLizszN M1\QNlczKGh? M1S1XWROW09? MX;pcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw MWWyOVY2QTd|MR?=
MUG-Chor  NYS0b4RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlztNE02KM7:TR?= NFvkbY8zPC92ODDo NFnEc|lKSzVyPUeuNFXjiImwTTDmc5IhPDiq MUOyOVY1ODF6NR?=
U-CH1  NGL6SFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTwPGNSOC13IN88US=> MWGyOE81QCCq NEfud2ZKSzVyPUmuNFPjiImwTTDmc5IhPDiq NEDTWVkzPTZ2MEG4OS=>
KATOIII NVTUTXN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXVNVAwOjBibl2= M3rTZ|Q5KGh? NHPCSVRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2PMeFI2PjN3MEW1
AGS  NXPkRXVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2X5SVExNzJyIH7N MYm0PEBp MYfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NYf0Z5BlOjV4M{WwOVU>
SACC-83 NWHBfYtRTnWwY4Tpc44hSXO|YYm= NYr1VWZuPSCwTR?= MWS0PEBp MnTF[IVkemWjc3XzJI52[2ynYYKg[ZhxemW|c3nvckBw\iCKSV[tNe6y NUT3Xo5EOjV2OEW2N|U>
INA-6 MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fqTVAuPTByIH7N NXj4XXJNPDhiaB?= NIPGTWxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MnjRNlUzQTZ7N{i=
U-266 NVf0TlF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DNXlAuPTByIH7N M{\3elQ5KGh? MUnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MVKyOVI6Pjl5OB?=
MOLP-8 MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LGNFAuPTByIH7N NH;rZ3Q1QCCq NIq3Z|NqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M33Rb|I2Ojl4OUe4
HG-1 M{fRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTDeGwxNTVyMDDuUS=> MVi0PEBp NXTvb5FXcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NInDZZQzPTJ7Nkm3PC=>
NCI-H929 NYrhPVd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\ZO44xNTVyMDDuUS=> NIiybVI1QCCq MoPmbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MlfWNlUzQTZ7N{i=
OPM-2 NFzxboNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYCwMVUxOCCwTR?= MW[0PEBp MXjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MYqyOVI6Pjl5OB?=
L-363 MnS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HhbVAuPTByIH7N MY[0PEBp M{XReolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1z3[lI2Ojl4OUe4
MOLP-2 M{fqcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnjblVMOC13MECgcm0> M2\Md|Q5KGh? M4mxbYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MUCyOVI6Pjl5OB?=
KMS-12-BM NXr2TVJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGwMVUxOCCwTR?= NYPnWZJvPDhiaB?= NVnvT2FJcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MX2yOVI6Pjl5OB?=
SK-MM-2 M3jD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPvd4gxNTVyMDDuUS=> M17sd|Q5KGh? MkS3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NXXXOVVGOjV{OU[5O|g>
U-266 NX\MZZFLSXCxcITvd4l{KEG|c3H5 MWewMVUxKG6P NEfqTWkzPCCq NFroc5dqdmS3Y3XzJIFxd3C2b4Ppdy=> NGjvTpMzPTJ7Nkm3PC=>
INA-6  MlXJRZBweHSxc3nzJGF{e2G7 M3vabVAuPTBibl2= MoLlNlQhcA>? MnnYbY5lfWOnczDhdI9xfG:|aYO= MlTlNlUzQTZ7N{i=
MCF7 NXy1T4tWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTtXYZNPzJiaB?= NXSxVHNMUUN3ME2xN{DDuSB4IH7N NWn6bIJpOjV{MkCyNlU>
MCF7-TamR6 MmPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDUOHY4OiCq NXTZe4VNUUN3ME24JOKyKDZibl2= MU[yOVIzODJ{NR?=
MCF7-TamR7 MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHYfo1QPzJiaB?= MkHTTWM2OD16INMxJFMhdk1? MYmyOVIzODJ{NR?=
MCF7-TamR8 M1;kWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjPNotSPzJiaB?= MUDJR|UxRTF3INMxJFYhdk1? Mlj3NlUzOjB{MkW=
MCF7-TamC3 NFHYUYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33YfFczKGh? M1Pkd2lEPTB;NjFCtUA{KG6P M13PVFI2OjJyMkK1
MCF7-TamC6 MkLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUi3NkBp MW\JR|UxRTZiwsGgNE4yKG6P M{DYOFI2OjJyMkK1
MDA-MB-231 MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu2OXc4OiCq Mn;JTWM2OD13INMxJFEhdk1? NVS5OJRDOjV{MkCyNlU>
SK-BR-3 MkfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXy2cXdvPzJiaB?= NUK3OWNMUUN3ME23JOKyKDBwMzDuUS=> MYmyOVIzODJ{NR?=
Eca109 MUXGeY5kfGmxbjDBd5NigQ>? NH[zdpAyNTVyIH7N NGnPd281QCCq MXPEUXNQ NVTIb4dCe3WycILld5NmeyC|dYL2bZZqdiCneIDy[ZN{cW:wIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M4ry[lI2OTN7M{m1
TE13 M3POXGZ2dmO2aX;uJGF{e2G7 M3PRSlEuPTBibl2= NWPpd3pHPDhiaB?= M{LSdGROW09? MVjzeZBxemW|c3XzJJN2en[rdnnuJIV5eHKnc4Ppc44hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MV6yOVE{QTN7NR?=
Eca109 NVPQN4pIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nkc|AuOTByIH7N NVnaSWxSOjRxNEigbC=> NEewVIhFVVOR MXfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NW\1VXRQOjVzM{mzPVU>
TE13 M2rYXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDlNE0yODBibl2= NH32S3ozPC92ODDo MoC0SG1UVw>? NUTRcpg5\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NYHaSVFQOjVzM{mzPVU>
MT-3 M3zNT2tqdmG|ZTDBd5NigQ>? MUm3NkBp MoPXSG1UVw>? MV;JR|UxRTJwOE[gxtEhOC53NDDuUUBnd3JiRGK0JIV5eHKnc4Ppc44> NVPheHJwOjR6Nk[1PFU>
MDA-MB-468 M1S5TWtqdmG|ZTDBd5NigQ>? NEDyeFE4OiCq NHLQPJBFVVOR M3n3WGlEPTB;MD6xNUDDuSByLkCxJI5OKG[xcjDEVlQh\XiycnXzd4lwdg>? NVLydFZ7OjR6Nk[1PFU>
SUM-159 M3HySmtqdmG|ZTDBd5NigQ>? NF7aO|E4OiCq NV3C[ZBkTE2VTx?= NYLoT2J{UUN3ME2xMlczKMLzIECuN|Mhdk1iZn;yJGRTPCCneIDy[ZN{cW:w NUH5fIJNOjR6Nk[1PFU>
MT-3 NGHz[ZVMcW6jc3WgRZN{[Xl? MWq3NkBp NXP1VnAzTE2VTx?= NHTONHlKSzVyPUW0MlEyKMLzIESuN|Ihdk1iZn;yJGRTPSCneIDy[ZN{cW:w MYKyOFg3PjV6NR?=
MDA-MB-468 M1vnd2tqdmG|ZTDBd5NigQ>? MVK3NkBp MVzEUXNQ NWK1PJY3UUN3ME2wMlA4KMLzIECuNFIhdk1iZn;yJGRTPSCneIDy[ZN{cW:w M{Hke|I1QDZ4NUi1
SUM-159 M{\IOmtqdmG|ZTDBd5NigQ>? NX7FXo1LPzJiaB?= MV3EUXNQ M3fwemlEPTB;NkmuOEDDuSB2LkKzJI5OKG[xcjDEVlUh\XiycnXzd4lwdg>? MWWyOFg3PjV6NR?=
MT-3 + NAC MWDLbY5ie2ViQYPzZZk> MVy3NkBp Ml;ISG1UVw>? M{XLcWlEPTB;NU[uNkDDuSB{LkC3JI5OKG[xcjDEVlUh\XiycnXzd4lwdg>? MUSyOFg3PjV6NR?=
MT-3 + SB203580 MlTET4lv[XOnIFHzd4F6 MknKO|IhcA>? NGrkNmVFVVOR MYrJR|UxRTN6LkSxJOKyKDVwMEKgcm0h\m:{IFTSOUBmgHC{ZYPzbY9v MlnYNlQ5PjZ3OEW=
DB MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUSxNEBvVQ>? MoXsNlQhcA>? MlTRSG1UVw>? MXvpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36= NXjv[WNlOjR2OE[1PVU>
SU-DHL-8 NUPDWFJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTzNVAhdk1? NYrNbXhkOjRiaB?= NVjUcpRrTE2VTx?= MYHpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36= NF76TW4zPDR6NkW5OS=>
WSU-DLCL2 M4GwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGxNEBvVQ>? NV\PZZF5OjRiaB?= NUS4S2dyTE2VTx?= MnvFbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u MlfDNlQ1QDZ3OUW=
ACC-2 NYjUPFBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TuRVAuOTByIH7N Mn\zNlQhcA>? M3nt[YlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1jDXFI1OzdyOUm1
ACC-2 MlzIRZBweHSxc3nzJGF{e2G7 NUPmNVNLOC1{MDDuUS=> NEPsXY8zPCCq NXPsWoZ4cW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MW[yOFM4ODl7NR?=
ACC-2 MnjoSpVv[3Srb36gRZN{[Xl? M2\YcFAuOjBibl2= NFHMN|MzPCCq M{XkRYlv[3KnYYPld{B1cGViY3;ueoVze2mxbjDv[kBNSzOLIITvJGxEO0mL M2DacFI1OzdyOUm1
BFTC905 M4O1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVOwMVExODBibl2= M1;HV|Q5KGkEoB?= MWDEUXNQ MnjKTWM2OD1{MDDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NH3vVnIzPDJ7N{[0OC=>
T24 NVXxS3pFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{T1R|AuOTByMDDuUS=> Ml3nOFghcMLi MYHEUXNQ NH;He2RKSzVyPUKwJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MXWyOFI6PzZ2NB?=
TSGH8301  Mnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojoNE0yODByIH7N MWC0PEBpyqB? MofQSG1UVw>? MXXJR|UxRTJyIH7NMEBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MoC1NlQzQTd4NES=
BFTC909 MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP5NE0yODByIH7N NYfxNJltPDhiaNMg M{jx[2ROW09? M3rtcWlEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MmPQNlQzQTd4NES=
BFTC905 M37MdmFxd3C2b4Ppd{BCe3OjeR?= MVuyNEBvVQ>? M1P2TlQ5KGh? NVHVRVR6TE2VTx?= MXfpcoR2[2W|IHHwc5B1d3Orcx?= NX63fm5POjR{OUe2OFQ>
BFTC905 NU\IZolRTnWwY4Tpc44hSXO|YYm= M{KzNVIxKG6P NH3iXnM1QCCq NGPrbI9FVVOR M4r0XYRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBNSzOELVnJ NVr2VZMxOjR{OUe2OFQ>
A2780p MkDHSpVv[3Srb36gRZN{[Xl? M3H6SFAuOTByIH7N NVW5S5dTOjRiaB?= NXfzNJg6TE2VTx?= MlrrbY5lfWOnczDTeZJ3cX[rbjDkc5dvemWpdXzheIlwdsLi MoXmNlQzPjJ6N{W=
A2780cis MV7GeY5kfGmxbjDBd5NigQ>? NFnXWmExNTFyMDDuUS=> Mn31NlQhcA>? Mo\KSG1UVw>? MlXGbY5lfWOnczDTeZJ3cX[rbjDkc5dvemWpdXzheIlwdsLi NFHQU4gzPDJ4Mki3OS=>
A2780p NIrjeIlCeG:ydH;zbZMhSXO|YYm= MVy1MVExOCCwTR?= MoHSNlQwPDhiaB?= NH7sVGVFVVOR MWfpcoNz\WG|ZYOgZZBweHSxc3nzJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy MVWyOFI3Ojh5NR?=
A2780cis NV7wfYZwSXCxcITvd4l{KEG|c3H5 NXW5XVU4PS1zMECgcm0> MUmyOE81QCCq MkP0SG1UVw>? NE\3fWVqdmO{ZXHz[ZMh[XCxcITvd4l{KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz M4LabVI1OjZ{OEe1
SH-SY5Y M2Htd2Fxd3C2b4Ppd{BCe3OjeR?= MXWxM|ExNzFyMDFCuW0> M1;3VFczKGh? NXzsO2RVTE2VTx?= MoLGbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MnvaNlQzPTR3NkC=
HL-60 NEPWfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G1W|czyqCq NXP0TJZYTE2VTx?= MmL2TWM2OD1yLkOgcm0> MlfvNlM3OTh6NkK=
U937  NXzqepB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWK3NuKhcA>? NFTkcGdFVVOR MnfGTWM2OD1yLkigcm0> NUTjUZE6OjN4MUi4OlI>
HL-60  MX3GeY5kfGmxbjDBd5NigQ>? M1ri[lHDqM7:TR?= M{HRNVYwOTJxMkSgbC=> NYnT[WlmTE2VTx?= NVziV2xpcW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4Yhe3W{dnn2bY4> MUiyN|YyQDh4Mh?=
U937  NIT6b|lHfW6ldHnvckBCe3OjeR?= MVixxsDPxE1? M4LE[FYwOTJxMkSgbC=> NWOxSohyTE2VTx?= NHPBOIdqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kB{fXK4aY\pci=> NH;IeFUzOzZzOEi2Ni=>
HL-60 NIrQWIhCeG:ydH;zbZMhSXO|YYm= MXSwMlEwOSEQvF2= NX;CeIlyQCCq NEnUOJdFVVOR NVS1S5IycW6mdXPld{BieG:ydH;zbZM> NU\oUGdlOjN4MUi4OlI>
Sk-NEP-1  MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVOxMVExODByIH7N NXi0THBrOjRiaB?= NV\UUGliTE2VTx?= NYHEbmxxUUN3ME2xNFAhdk1? MUmyN|I3PzZ7OR?=
SK-NEP-1  M2HLTGFxd3C2b4Ppd{BCe3OjeR?= MkXvOVAwOTByIH7N MlvONVIwOjRiaB?= M1jSXGROW09? NVjz[|l3cW6mdXPld{BieG:ydH;zbZM> MoPoNlMzPjd4OUm=
TC-32 MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjoV5NVOC5zLUGwNFAhdk1? MkS1SWM2OD1|LkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NEP5TIEzOjl4MUe2Ny=>
TC-71 MoPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjMbYsxOC5zLUGwNFAhdk1? Ml34SWM2OD13Lkegcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M4HOb|IzQTZzN{[z
SK-ES-1 NXHBTXA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml60NE4yNTFyMECgcm0> MWrFR|UxRTJwODDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYeyNlk3OTd4Mx?=
RD-ES NHTqSpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVuwMlEuOTByMDDuUS=> NGTpZnFGSzVyPU[uNkBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M3vw[|IzQTZzN{[z
HEK293 MlTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPDNE4yNTFyMECgcm0> M17Xd2VEPTB;MkOuNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NUHSWlJqOjJ7NkG3OlM>
M059J NGXKN|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYqwMVUxKG6P M3[wU|Q5KGh? NELaT49qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NGfMfpczOjd5MEGxNC=>
M059K MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjy[lNOOC13MDDuUS=> NFnVcZU1QCCq NV\wZVB{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NILUTlAzOjd5MEGxNC=>
M059J MlrsRZBweHSxc3nzJGF{e2G7 M3PQUlMxKG6P M1riUFI1KGh? MYPpcoR2[2W|IHHwc5B1d3Orcx?= MYOyNlc4ODFzMB?=
M059K NV;VfFF4SXCxcITvd4l{KEG|c3H5 NHfXeXQ{OCCwTR?= MUSyOEBp M4LMcIlv\HWlZYOgZZBweHSxc3nz NGraRm8zOjd5MEGxNC=>
PANC-1 NY\UcIc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYGwMlAyNTFyMECgcm0> MXq0PEBp NEDrS4NKSzVyPUOuOlkhdk1? NVrTNWFuOjJ5MkO4O|E>
MIAPaCa-2 MkCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm2NE4xOS1zMECwJI5O NETm[Is1QCCq NEG2bpFKSzVyPUK5MlM3KG6P MlXaNlI4OjN6N{G=
BxPC-3 NHvYOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3VNE4xOS1zMECwJI5O M{LRSVQ5KGh? M1rjWmlEPTB;M{CuNlYhdk1? M4TS[VIzPzJ|OEex
PANC-1 NFn6SHpHfW6ldHnvckBCe3OjeR?= NFvsV48xNTFyMECgcm0> M1\RRlI1KGh? NFH6VlhqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHhKSVBiYX7kJJN2en[rdnnuJIV5eHKnc4Ppc44> NYLTO3NROjJ5MkO4O|E>
MIAPaCa-2 MlzRSpVv[3Srb36gRZN{[Xl? NVvMfmpnOC1zMECwJI5O NUTRc21GOjRiaB?= NVjoPXJCcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBZUUGSIHHu[EB{fXK4aY\pckBmgHC{ZYPzbY9v NH70VXczOjd{M{i3NS=>
BxPC-3 NYrkZ3kzTnWwY4Tpc44hSXO|YYm= M4K3VlAuOTByMDDuUS=> NFnkUHQzPCCq NHPibpRqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHhKSVBiYX7kJJN2en[rdnnuJIV5eHKnc4Ppc44> MXeyNlczOzh5MR?=
RPMI-7951 M1Htb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLDW4JxT0l3ME2zMlIhdk1? MWqyNVc{PzVyMh?=
SK-MEL-5 NFPVV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2D4WmdKPTB;ND6yJI5O MmDHNlE4Ozd3MEK=
A375 M2XGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXMSG0zT0l3ME22MlMhdk1? M4nTTlIyPzN5NUCy
SK-MEL-28 M3nXemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTBcHg3T0l3ME23MlYhdk1? NEH0Vo0zOTd|N{WwNi=>
SK-MEL-2 NI\zUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\RS2k2OD1zMTDuUS=> NFrmZ4UzOTd|N{WwNi=>
DB MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:3VolMPDkEoHi= NVm1bGt1T0l3ME2zMlUhdk1? NVXCV25XOjF{M{e1NFg>
Pfeiffer MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7BOlI1QMLiaB?= Mn;GS2k2OD1|Lkmgcm0> NUW4e|doOjF{M{e1NFg>
SU-DHL-5 NFXiS4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUO0POKhcA>? M3jWWGdKPTB;MD6yN{BvVQ>? MYiyNVI{PzVyOB?=
SU-DHL-8 M17rR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlyxOFjDqGh? MUDHTVUxRTFwNDDuUS=> MYWyNVI{PzVyOB?=
WSU-DLCL-2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7KcXQ1QMLiaB?= MV\HTVUxRTFwNDDuUS=> MkLBNlEzOzd3MEi=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Survivin / XIAP / Caspase-7 / Caspase-9 / Caspase-3 / Cleaved Caspase-8 / PARP; 

PubMed: 26771139     


YM155 treatment decreased survivin expression without affecting XIAP and induced cleavage of caspases. Protein expression (caspase-3, -7, -9, -8, PARP) was detected by Western Blot analysis. 

β-catenin / c-Myc / Cyclin D1 / CD44 ; 

PubMed: 26771139     


YM155 inhibited expression of CSC molecules. SGC-7901 cells were treated with YM155 at indicated doses for 24 hours. The protein levels of genes were determined by Western Blot.

p-STAT3 / STAT3 ; 

PubMed: 22723871     


Levels of phosphorylated STAT3 and expression of survivin were analyzed by Western blotting after a 24-hours treatment with YM155 and 48 hours after transfection of 40 nM siRNA.

26771139 22723871
Immunofluorescence
EGFR; 

PubMed: 22723871     


YM155 (10 nM) induced the nuclear EGFR accumulation. PANC-1 cells were stained with anti-EGFR, anti-Alexa Fluor 488, and DAPI after the YM155 treatment. Scale bars: 10 µm.

PARP-1 / PAR ; 

PubMed: 26090615     


A. Nuclear accumulation of active PARP-1 in KYSE410 cells after 12 h of YM155 treatment was evaluated using immunofluorescent analysis. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. C. Accumulation of the poly-ADP polymer in KYSE410 was evaluated using immunofluorescent analysis after YM155 treatment for 12 h. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. 

22723871 26090615
Growth inhibition assay
Cell viability; 

PubMed: 29636860     


Cells were grown in 96-well plates for 24 h and treated with the indicated concentrations of YM155 or docetaxel for 72 h, and cell survival was determined by MTT assay.

29636860
In vivo YM155 completely inhibits the tumor growth of PC-3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue. Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts. [1] The combination therapy with YM155 and γ-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice. [2]

Protocol

Kinase Assay:

[1]

- Collapse

Promoter-luciferase reporter assay:

A 2,767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5
Cell Research:

[1]

- Collapse
  • Cell lines: Hormone refractory prostate cancer cell lines (PC-3, PPC-1, DU145, TSU-Pr1 and 22Rv1) and malignant melanoma cell lines (SK-MEL-5 and A375)
  • Concentrations: ~ 100 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded in 96-well plates at a density of 5-40 × 103. YM155 is dissolved in DMSO and added to cells for 48 hours. Then the cell count is determined by sulforhodamine B assay.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: PC-3 s.c. (orthotopic) xenografts in male nude mice (BALB/c nu/nu)
  • Dosages: 5 mg/kg
  • Administration: Subcutaneous injection as a 3-day continuous infusion per week for 3 weeks by an implanted micro-osmotic pump
    (Only for Reference)

Solubility (25°C)

In vitro Water 89 mg/mL (200.77 mM)
DMSO 55 mg/mL (124.07 mM)
Ethanol 6 mg/mL (13.53 mM)
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 443.29
Formula

C20H19BrN4O3

CAS No. 781661-94-7
Storage powder
in solvent
Synonyms N/A
Smiles CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Survivin Signaling Pathway Map

Related Survivin Products

Tags: buy YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) supplier | purchase YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) cost | YM155 (Sepantronium Bromide) manufacturer | order YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID